Inspire Medical Systems (NYSE:INSP) Insider Jason Kelly Sells 963 Shares of Stock

Inspire Medical Systems, Inc. (NYSE:INSP) insider Jason Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Inspire Medical Systems Trading Down 0.8%

Shares of INSP stock traded down $0.47 during mid-day trading on Tuesday, reaching $59.25. The stock had a trading volume of 385,365 shares, compared to its average volume of 860,634. The business’s fifty day moving average is $48.39 and its 200-day moving average is $53.75. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 4.54 and a beta of 0.70. Inspire Medical Systems, Inc. has a 1-year low of $38.91 and a 1-year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm’s revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, analysts forecast that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Inspire Medical Systems during the 2nd quarter valued at about $211,341,000. Wellington Management Group LLP acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth approximately $203,929,000. Wasatch Advisors LP grew its position in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares in the last quarter. Morgan Stanley grew its position in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares in the last quarter. Finally, Deerfield Management Company L.P. increased its holdings in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 5th. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective on the stock. in a report on Friday, May 22nd. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research report on Tuesday, August 4th. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $68.00.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.